Page 146 - 《中国药房》2026年5期

[31] HAO Y S，CHAPUY B，MONTI S，et al. Selective JAK2 date on development of small-molecule STAT3 inhibitors
inhibition specifically decreases Hodgkin lymphoma and for cancer therapy：from phosphorylation inhibition to pro‐
mediastinal large B-cell lymphoma growth in vitro and in tein degradation[J]. J Med Chem，2021，64（13）：8884-
vivo[J]. Clin Cancer Res，2014，20（10）：2674-2683. 8915.
[32] PAN Y R，CHEN C C，CHAN Y T，et al. STAT3-coordi‐ [42] LI X，WEI Y Q，WEI X W. Napabucasin，a novel inhibitor
nated migration facilitates the dissemination of diffuse of STAT3，inhibits growth and synergises with doxorubi‐
large B-cell lymphomas[J]. Nat Commun，2018，9（1）： cin in diffuse large B-cell lymphoma[J]. Cancer Lett，
3696. 2020，491：146-161.
[33] LAI P S，ROSA D A，MAGDY ALI A，et al. A STAT in‐ [43] TOLCHER A，FLAHERTY K，SHAPIRO G I，et al. A
hibitor patent review：progress since 2011[J]. Expert Opin first-in-human phase I study of OPB-111077，a small-
Ther Pat，2015，25（12）：1397-1421. molecule STAT3 and oxidative phosphorylation inhibitor，
[34] WANG H Q，MAN Q W，HUO F Y，et al. STAT3 pathway in patients with advanced cancers[J]. Oncologist，2018，23
in cancers：past，present，and future[J]. MedComm，2022， （6）：658-e72.
3（2）：e124. [44] REILLEY M J，MCCOON P，COOK C，et al. STAT3 anti‐
[35] PHILIPS R L，WANG Y X，CHEON H，et al. The JAK- sense oligonucleotide AZD9150 in a subset of patients
STAT pathway at 30：much learned，much more to do[J]. with heavily pretreated lymphoma：results of a phase 1b
Cell，2022，185（21）：3857-3876. trial[J]. J Immunother Cancer，2018，6（1）：119.
[36] MATSUOKA Y，NAKAYAMA H，YOSHIDA R，et al. IL- [45] ROSCHEWSKI M，PATEL M R，REAGAN P M，et al.
6 controls resistance to radiation by suppressing oxidative Phase Ⅰ study of acalabrutinib plus danvatirsen
stress via the Nrf2-antioxidant pathway in oral squamous （AZD9150） in relapsed/refractory diffuse large B-cell
cell carcinoma[J]. Br J Cancer，2016，115（10）：1234- lymphoma including circulating tumor DNA biomarker as‐
1244. sessment[J]. Clin Cancer Res，2023，29（17）：3301-3312.
[37] CHEN Q N，LU C Y，LI D N，et al. CDK1 inhibitor RO- [46] RIBRAG V，LEE S T，RIZZIERI D，et al. A phase 1b
3306 enhances BTKi potency in diffuse large B-cell lym‐ study to evaluate the safety and efficacy of durvalumab in
phoma by suppressing JAK2/STAT3 signaling[J]. Int J combination with tremelimumab or danvatirsen in patients
Biol Macromol，2025，297：139893. with relapsed or refractory diffuse large B-cell lymphoma
[38] TURKSON J，KIM J S，ZHANG S M，et al. Novel pepti‐ [J]. Clin Lymphoma Myeloma Leuk，2021，21（5）：309-
domimetic inhibitors of signal transducer and activator of 317.e3.
transcription 3 dimerization and biological activity[J]. [47] HINTERNDORFER M，SPITERI V A，CIULLI A，et al.
Mol Cancer Ther，2004，3（3）：261-269. Targeted protein degradation for cancer therapy[J]. Nat
[39] SIDDIQUEE K A Z，GUNNING P T，GLENN M，et al. Rev Cancer，2025，25（7）：493-516.
An oxazole-based small-molecule STAT3 inhibitor modu‐ [48] ZHOU J J，TISON K，ZHOU H B，et al. STAT5 and
lates STAT3 stability and processing and induces antitu‐ STAT3 balance shapes dendritic cell function and tumour
mor cell effects[J]. ACS Chem Biol，2007，2（12）： immunity[J]. Nature，2025，643（8071）：519-528.
787-798. [49] WANG Z J，LIAO X T，HE H Q，et al. Targeting the
[40] JING N J，ZHU Q Q，YUAN P，et al. Targeting signal STAT3 pathway with STAT3 degraders[J]. Trends Pharma‐
transducer and activator of transcription 3 with G-quartet col Sci，2024，45（9）：811-823.
oligonucleotides：a potential novel therapy for head and （收稿日期：2025-08-18 修回日期：2026-02-25）
neck cancer[J]. Mol Cancer Ther，2006，5（2）：279-286. （编辑：孙 冰）
[41] DONG J Y，CHENG X D，ZHANG W D，et al. Recent up‐

· 688 · China Pharmacy 2026 Vol. 37 No. 5 中国药房 2026年第37卷第5期